Premium
Peritoneal tuberculosis due to multidrug‐resistant M ycobacterium tuberculosis
Author(s) -
Esposito Susanna,
Bosis Samantha,
Canazza Lorena,
Tenconi Rossana,
Torricelli Maurizio,
Principi Nicola
Publication year - 2013
Publication title -
pediatrics international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.49
H-Index - 63
eISSN - 1442-200X
pISSN - 1328-8067
DOI - 10.1111/j.1442-200x.2012.03735.x
Subject(s) - medicine , tuberculosis , multiple drug resistance , microbiology and biotechnology , antibiotics , pathology , biology
The emergence of drug‐resistant M ycobacterium tuberculosis has been widely reported throughout the world, but there are very few data regarding children. We describe the case of a 14‐year‐old Peruvian adolescent who had been living in I taly since the age of 8 years and was diagnosed as having peritoneal tuberculosis ( TB ). While she was receiving first‐line anti‐ TB therapy, she developed pyrazinamide‐associated thrombocytopenia and cultures revealed a multidrug‐resistant strain of M ycobacterium tuberculosis . Pyrazinamide, rifampicin and isoniazid were replaced by moxifloxacin, which was continued for 9 months together with ethambutol. The patient recovered without experiencing any drug‐related adverse event or the recurrence of TB in the following year. In conclusion, this case illustrates some of the problems that can arise when multidrug‐resistant TB has to be treated in children and adolescents, and also highlights the fact that further studies are needed to clarify which drugs should be used and for how long.